Nurix Therapeutics, Inc. (NRIX)
Stock Price:
$42.31 USD
3.07 (7.82%)
Updated November 30, 2:28 PM EST - Market open
Key Info
| Market Cap |
1.64B |
| Revenue (ttm) |
12.99M |
| Net Income (ttm) |
-36.85M |
| Shares Out |
38.86M |
| EPS (ttm) |
-0.95 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 30 |
| Last Price |
$42.31 |
| Previous Close |
$39.24 |
| Change ($) |
3.07 |
| Change (%) |
7.82% |
| Day's Open |
39.56 |
| Day's Range |
37.95 - 42.81 |
| Day's Volume |
59,714 |
| 52-Week Range |
16.05 - 42.81 |
More Stats
| Market Cap |
1.64B |
| Enterprise Value |
1.29B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
38.86M |
| Float |
n/a |
| EPS (basic) |
n/a |
| EPS (diluted) |
-0.95 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
844,308 |
| Short Ratio |
6.79 |
| Short % of Float |
n/a |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
126.53 |
| PB Ratio |
4.77 |
| Revenue |
12.99M |
| Operating Income |
n/a |
| Net Income |
-36.85M |
| Free Cash Flow |
n/a |
| Net Cash |
354.41M |
| Net Cash / Share |
9.12 |
| Gross Margin |
-107.06% |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (5)
| Buy |
4 |
| Overweight |
1 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$36.60*
(-13.50% downside)
Low
34.0
Current: $42.31
High
40.0
Target: 36.60
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -53.35 | -47.19 |
| Net Income | -21.70 | -9.43 |
| Shares Outstanding | 3.29 | 2.82 |
| Earnings Per Share | -6.59 | -3.35 |
| Cash & Equivalents | 37.89 | 39.21 |
| Net Cash / Debt | 37.89 | 39.21 |
| Assets | 44.05 | 45.40 |
| Liabilities | 53.57 | 34.05 |
| Book Value | -57.71 | -36.85 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Nurix Therapeutics, Inc. |
| Country |
United States |
| Employees |
122 |
| CEO |
Arthur T. Sands |
Stock Information
| Ticker Symbol |
NRIX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: NRIX |
| IPO Date |
July 24, 2020 |
Description
Nurix Therapeutics, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's lead product candidates in preclinical stage include NX-2127, an orally available Bruton's tyrosine kinase degrader for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology indications. It also provides DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a class of enzymes that could modulate proteins within the cell. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc.; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was founded in 2009 and is headquartered in San Francisco, California.